In this issue:
Cardiovascular safety of testosterone replacement therapy
The FGF21 analogue pegozafermin for severe hypertriglyceridaemia
Zilebesiran, an RNA interference therapeutic agent for hypertension
Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid
Atorvastatin for anthracycline-associated cardiac dysfunction
Mortality trends after primary PCI for STEMI in Denmark
Cost-effectiveness of vericiguat in patients with HFrEF
Mineralocorticoid receptor antagonists are underutilised in patients with HFrEF
Phenotyping coronary plaque in patients with premature coronary artery disease
Stroke risk in women with AF
Please login below to download this issue (PDF)